National Advertising Division Recommends T-Mobile Modify or Discontinue Claim About the Ability to Watch Live Major League Baseball Games on MLB.tv

New York, NY – August 22, 2023 – The National Advertising Division (NAD) of BBB National Programs recommended that T-Mobile US, Inc. discontinue the claim that T-Mobile customers who download the T-Mobile Tuesdays App will be able to watch “every regular season [Major League Baseball] game live or on demand,” or modify the claim to make clear which categories of live games are available with the MLB.tv benefit.

In this Fast-Track SWIFT challenge, the claim at issue, which appeared in an instructional YouTube video, was challenged by AT&T Services, Inc. Fast-Track SWIFT is an expedited process designed for single-issue advertising cases brought to NAD. 

Although T-Mobile voluntarily modified the challenged claim during the proceeding to say that with the MLB.tv app, T-Mobile customers will be able to “enjoy every 2023 out-of-market, regular season game live or on demand,” a modification that made the claim accurate and not misleading, T-Mobile did not represent that it would permanently modify the claim to include “out-of-market” in any other future executions of the advertising. Therefore, NAD addressed the claim as it was originally challenged.

NAD determined that the challenged claim reasonably conveys a message that T-Mobile customers will be able to watch all regular season games live, whether they are nationally televised games, in-market games, or out-of-market games. 

NAD concluded that such a message is not supported because, while all games that have been played already are available for viewing on demand, all games are not available live. NAD also noted that the “blackouts and other restrictions apply” disclosure does not cure the challenged claim as it contradicts the main message that all games are available live.

In its advertiser statement, T-Mobile stated that it “will comply with NAD’s decision” and that it “appreciates NAD’s recognition that the voluntary change it already made to [its] instructional video was sufficient to address AT&T’s alleged concerns."

All BBB National Programs case decision summaries can be found in the case decision library. For the full text of NAD, NARB, and CARU decisions, subscribe to the online archive. Per NAD Procedures, this release shall not be used for advertising or promotional purposes.

 

Subscribe to the Ad Law Insights or Privacy Initiatives newsletters for an exclusive monthly analysis and insider perspectives on the latest trends and case decisions in advertising law and data privacy.

 

 

 

 

Latest Decisions

Decision

National Advertising Division Recommends Dr. Luke Healthcare Discontinue Treatment Claims for its Fungal Nail Renewal Product

New York, NY – July 24, 2024 – The National Advertising Division recommended Dr. Luke Healthcare discontinue certain claims for Dr. Luke’s Fungal Nail Renewal product, including health-related claims, natural claims, and claims that a doctor recommends the product or that it treats a medical condition.

Read the Decision Summary
Decision

National Advertising Division Finds Flag Image on Kendamil Infant Formula Packaging Conveys Supported Message about Products’ Origin

New York, NY – July 17, 2024 – In a Fast-Track SWIFT challenge, the National Advertising Division determined that use of a flag image on product packaging for Kendal Nutricare’s Kendamil infant formula reasonably conveys a supported message about the products’ origin. 

Read the Decision Summary
Decision

In National Advertising Division Case, GuruNanda Voluntarily Discontinues Claims Made through Influencers for Coconut Pulling Oil Products

New York, NY – July 16, 2024 – The National Advertising Division has closed a Fast-Track SWIFT challenge regarding claims that GuruNanda’s coconut pulling oil products can “naturally reverse a cavity” and “reverse cavities.” 

Read the Decision Summary
Decision

National Advertising Division Refers Health-Related Advertising Claims for Prolacta’s Human Milk Fortifier to Regulatory Agencies

New York, NY – July 15, 2024 – The National Advertising Division will refer advertising claims made by Prolacta Bioscience for its Human Milk Fortifier to the Federal Trade Commission (FTC) and Food and Drug Administration (FDA) for review.

Read the Decision Summary